Gazyva Side Effects

Generic Name: obinutuzumab

Note: This page contains information about the side effects of obinutuzumab. Some of the dosage forms included on this document may not apply to the brand name Gazyva.

Not all side effects for Gazyva may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to obinutuzumab: intravenous solution

Along with its needed effects, obinutuzumab (the active ingredient contained in Gazyva) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking obinutuzumab:

More common
  • Back pain
  • black, tarry stools
  • bleeding gums
  • blood in the urine or stools
  • chest tightness
  • chills
  • cough or hoarseness
  • fever
  • flushing
  • headache
  • lower back or side pain
  • nausea and vomiting
  • painful or difficult urination
  • pale skin
  • pinpoint red spots on the skin
  • sore throat
  • trouble breathing
  • troubled breathing with exertion
  • ulcers, sores, or white spots in the mouth
  • unusual bleeding or bruising
  • unusual tiredness or weakness
Less common
  • Joint pain, stiffness, or swelling
  • lower back, side, or stomach pain
  • swelling of the feet or lower legs
Incidence not known
  • Blurred vision
  • confusion
  • convulsions
  • dark urine
  • dizziness
  • drowsiness
  • general tiredness and weakness
  • headache
  • light-colored stools
  • upper right abdominal or stomach pain
  • yellow eyes and skin

Some side effects of obinutuzumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known
  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site

For Healthcare Professionals

Applies to obinutuzumab: intravenous solution

General

The most frequently reported side effects included infusion reactions, neutropenia, thrombocytopenia, anemia, pyrexia, cough and musculoskeletal disorders.

Cardiovascular

Frequency not reported: Worsening of preexisting cardiac conditions with fatalities

Hematologic

Very common (10% or more): Neutropenia (40%), thrombocytopenia (15%), anemia (12%)
Common (1% to 10%): Leukopenia (7%)

Hepatic

Very common (10% or more): AST (SGOT) increased (28%), ALT (SGPT) increased (25%)

Metabolic

Very common (10% or more): Hypocalcemia (32%), hyperkalemia (31%), hyponatremia (29%), hypoalbuminemia (22%), alkaline phosphatase increased (16%), hypokalemia (13%)
Common (1% to 10%): Grade 3 or 4 tumor lysis syndrome (2%)

Musculoskeletal

Very common (10% or more): Musculoskeletal disorders including pain (17%)

Nervous system

Frequency not reported: Progressive multifocal leukoencephalopathy

Other

Very common (10% or more): Infusion related reactions (69%), pyrexia (10%)

Renal

Very common (10% or more): Creatinine increased (28

Respiratory

Very common (10% or more): Cough (10%)

Immunologic

Very common (10% or more): Positive test for anti-obinutuzumab (the active ingredient contained in Gazyva) antibodies (13%)
Common (1% to 10%): Infection (9%)
Frequency not reported: Hepatitis B reactivation

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web5)